Radiation safety issues in Y-90 microsphere selective hepatic radioembolization therapy: Possible radiation exposure from the patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim Y.-C. | - |
dc.contributor.author | Kim Y.-H. | - |
dc.contributor.author | Uhm S.-H. | - |
dc.contributor.author | Seo Y.S. | - |
dc.contributor.author | Park E.-K. | - |
dc.contributor.author | Oh S.-Y. | - |
dc.contributor.author | Jeong E. | - |
dc.contributor.author | Lee S. | - |
dc.contributor.author | Choe J.-G. | - |
dc.date.available | 2020-11-03T07:44:00Z | - |
dc.date.issued | 2010-12 | - |
dc.identifier.issn | 1869-3474 | - |
dc.identifier.issn | 1869-3482 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/15444 | - |
dc.description.abstract | Purpose: The purpose of this study was to estimate the possible external radiation dose to other individuals from patients treated with Y-90 resin microspheres for unresectable hepatocellular carcinoma. Methods: We designed the study prospectively to estimate the possible radiation dose to other individuals from patients who had been treated with Y-90 microspheres for unresectable hepatocellular carcinoma. We estimated the total effective dose equivalent (TEDE) using two methods: 'theoretical' TEDEs according to the administered activity and 'measured' TEDE based on the 'measured' ambient radiation exposure rate. We compared the results from each method to determine when we can release patients from confinement at the earliest time complying with the patient release criteria. Results: A total of 20 administrations of Y-90 resin microspheres were done in 18 patients. The average administered activity was 1.2±0.77 (0.28-2.97) GBq. The 'theoretical' TEDEs were in the range of 0.8-10 μSv. The 'measured' TEDEs were in the range of 2.31-185 μSv. The measured TEDEs tend to be higher than the theoretical TEDEs. The values of theoretical and measured TEDE were both far less than 1 mSv, the upper limit at which the licensee can release a patient without any written documents. Conclusion: The effective dose equivalent caused by the Y-90 microsphere administered patient is very low. It is safe in terms of radiation safety to the other individuals when Y-90 microsphere radioembolization therapy is done with dose less than 3 GBq. Because the measured TEDE tends to be higher than the theoretical TEDE, it is recommended to use 'measured' TEDE for determining patient release. © Korean Society of Nuclear Medicine 2010. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.title | Radiation safety issues in Y-90 microsphere selective hepatic radioembolization therapy: Possible radiation exposure from the patients | - |
dc.type | Article | - |
dc.publisher.location | 독일 | - |
dc.identifier.doi | 10.1007/s13139-010-0047-7 | - |
dc.identifier.scopusid | 2-s2.0-79952737314 | - |
dc.identifier.bibliographicCitation | Nuclear Medicine and Molecular Imaging, v.44, no.4, pp 252 - 260 | - |
dc.citation.title | Nuclear Medicine and Molecular Imaging | - |
dc.citation.volume | 44 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 252 | - |
dc.citation.endPage | 260 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001501694 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordPlus | microsphere | - |
dc.subject.keywordPlus | sir sphere | - |
dc.subject.keywordPlus | unclassified drug | - |
dc.subject.keywordPlus | yttrium 90 | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | aged | - |
dc.subject.keywordPlus | article | - |
dc.subject.keywordPlus | chemoembolization | - |
dc.subject.keywordPlus | clinical article | - |
dc.subject.keywordPlus | controlled clinical trial | - |
dc.subject.keywordPlus | dosimetry | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | intermethod comparison | - |
dc.subject.keywordPlus | liver cell carcinoma | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | outcome assessment | - |
dc.subject.keywordPlus | patient assessment | - |
dc.subject.keywordPlus | patient safety | - |
dc.subject.keywordPlus | priority journal | - |
dc.subject.keywordPlus | prospective study | - |
dc.subject.keywordPlus | radiation exposure | - |
dc.subject.keywordPlus | radiation safety | - |
dc.subject.keywordPlus | radioisotope decay | - |
dc.subject.keywordAuthor | Hepatocellular carcinoma | - |
dc.subject.keywordAuthor | Liver tumor | - |
dc.subject.keywordAuthor | Radiation safety | - |
dc.subject.keywordAuthor | Selective hepatic radio-embolization therapy | - |
dc.subject.keywordAuthor | Y-90 microsphere | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.